Approved IL-6 receptor (IL-6R) inhibitors tocilizumab and sarilumab have shown good effectiveness and tolerance as monotherapy or combination treatment in RA patients who do not respond well to csDMARDs [4,7]. The gene discussed is IL6R; the disease is rheumatoid arthritis.